News & Updates
Filter by Specialty:
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
20 May 2022
byAudrey Abella
SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
20 May 2022Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
20 May 2022
Patients who have had a stroke despite being on nonvitamin K antagonist oral anticoagulant therapy are likely to experience a recurrent ischaemic stroke episode and bleeding, according to data from the RENO-EXTEND Study.
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
20 May 2022Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022
byRoshini Claire Anthony
Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.